Scottish Medicines Consortium
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
February 5, 2026Research and Development BMS, Scottish Medicines Consortium, colorectal cancer, oncology
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination with Yervoy (ipilimumab), by the …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
February 4, 2026Research and Development Astellas Pharma, Scottish Medicines Consortium, Vyloy, gastric cancer, oncology
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that Vyloy (zolbetuximab), in combination with …
Novartis receives SMC approval for early breast cancer treatment
November 11, 2025Research and Development Novartis, Scottish Medicines Consortium, breast cancer, nhs scotland
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval for use within NHS Scotland …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
October 29, 2025Pharma&, Rubraca, Scottish Medicines Consortium, nhs scotland, oncology, ovarian cancer
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by the Scottish Medicines Consortium (SMC) …
Treatment for serious eye disease approved in Scotland
June 12, 2025Market Access, Marketing Services, Research and Development, Sales and Marketing LYTENAVA, Opthalmology, Scottish Medicines Consortium, clinical programme, european union, eye disease, market approval, strategic partnership, united kingdom, wet age-related macular degeneration
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …
Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
April 8, 2025Research and Development R&D, Rare Diseases, Scottish Medicines Consortium, ipsen, primary biliary cholangitis (PBC)
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS Scotland for the treatment of …
Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes
April 15, 2020Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma
Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …
Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease
December 12, 2019Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales
Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …
Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma
October 8, 2019Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma
News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …
Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer
October 7, 2019Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma
The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …
Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation
July 11, 2019Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma
Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …
MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma
May 14, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma
MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
Rare lung cancer drug approved in Scotland
August 14, 2018Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer
The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
